Magnus Thorsten Jensen

Magnus Thorsten Jensen

Auto-generated profile, based on publicly available information

Magnus Thorsten Jensen

Steno Diabetes Center Copenhagen, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2013 in Heart
Verified
Journal Article
Open access
MJMagnus Thorsten Jensen
Magnus Thorsten Jensen
PSPoul Suadicani
Poul Suadicani
HHHans Ole Hein
Hans Ole Hein
FGFinn Gyntelberg
Finn Gyntelberg
Objective: To examine whether elevated resting heart rate (RHR) is an independent risk factor for mortality or a mere marker of physical fitness (VO2Max). Methods: This was a prospective cohort study: the Copenhagen Male Study, a longitudinal study of healthy middle-aged employed men. Subjects with sinus rhythm and without known cardiovascular disease or diabetes were included. RHR was assessed from a resting ECG at study visit in 1985–1986. VO2Max was determined by the Åstrand bicycle ergometer test in 1970–1971. Subjects were classified into categories according to level of RHR. Associations with mortality were studied in multivariate Cox models adjusted for physical fitness, leisure-time physical activity and conventional cardiovascular risk factors. Results: 2798 subjects were followed for 16 years. 1082 deaths occurred. RHR was inversely related to physical fitness (p90 had an HR (95% CI) of 3.06 (1.97 to 4.75). With RHR as a continuous variable, risk of mortality increased with 16% (10–22) per 10 beats per minute (bpm). There was a borderline interaction with smoking (p=0.07); risk per 10 bpm increase in RHR was 20% (12–27) in smokers, and 14% (4–24) in non-smokers. Conclusions: Elevated RHR is a risk factor for mortality independent of physical fitness, leisure-time physical activity and other major cardiovascular risk factors.


1 August 2018 in JACC
Verified
Journal Article
Closed access
JCJohan S.R. Clausen
Johan S.R. Clausen
JMJacob L. Marott
Jacob L. Marott
AHAndreas Holtermann
Andreas Holtermann
FGFinn Gyntelberg
Finn Gyntelberg
MJMagnus T. Jensen
Magnus T. Jensen

7 January 2019 in Thorax
Verified
Journal Article
Open access
PDF file
JFJilles M Fermont
Jilles M Fermont
KMKatya L Masconi
Katya L Masconi
MJMagnus T Jensen
Magnus T Jensen
RFRenata Ferrari
Renata Ferrari
VLValeria Amorim Pires Di Lorenzo
Valeria Amorim Pires Di Lorenzo
AWAngela M Wood
Angela M Wood
Background Conventional measures to evaluate COPD may fail to capture systemic problems, particularly musculoskeletal weakness and cardiovascular disease. Identifying these manifestations and assessing their association with clinical outcomes (ie, mortality, exacerbation and COPD hospital admission) is of increasing clinical importance. Objective To assess associations between 6 min walk distance (6MWD), heart rate, fibrinogen, C reactive protein (CRP), white cell count (WCC), interleukins 6 and 8 (IL-6 and IL-8), tumour necrosis factor-alpha, quadriceps maximum voluntary contraction, sniff nasal inspiratory pressure, short physical performance battery, pulse wave velocity, carotid intima-media thickness and augmentation index and clinical outcomes in patients with stable COPD. Methods We systematically searched electronic databases (August 2018) and identified 61 studies, which were synthesised, including meta-analyses to estimate pooled HRs, following Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results Shorter 6MWD and elevated heart rate, fibrinogen, CRP and WCC were associated with higher risk of mortality. Pooled HRs were 0.80 (95% CI 0.73 to 0.89) per 50 m longer 6MWD, 1.10 (95% CI 1.02 to 1.18) per 10 bpm higher heart rate, 3.13 (95% CI 2.14 to 4.57) per twofold increase in fibrinogen, 1.17 (95% CI 1.06 to 1.28) per twofold increase in CRP and 2.07 (95% CI 1.29 to 3.31) per twofold increase in WCC. Shorter 6MWD and elevated fibrinogen and CRP were associated with exacerbation, and shorter 6MWD, higher heart rate, CRP and IL-6 were associated with hospitalisation. Few studies examined associations with musculoskeletal measures. Conclusion Findings suggest 6MWD, heart rate, CRP, fibrinogen and WCC are associated with clinical outcomes in patients with stable COPD. Use of musculoskeletal measures to assess outcomes in patients with COPD requires further investigation. Trial registration number CRD42016052075.

27 April 2011 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
MJMagnus T Jensen
Magnus T Jensen
JMJacob L Marott
Jacob L Marott
KAKristine H Allin
Kristine H Allin
BNBørge G Nordestgaard
Børge G Nordestgaard
GJGorm B Jensen
Gorm B Jensen
Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.

8 November 2012 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
MJMagnus Thorsten Jensen
Magnus Thorsten Jensen
JMJacob L. Marott
Jacob L. Marott
PLPeter Lange
Peter Lange
JVJørgen Vestbo
Jørgen Vestbo
PSPeter Schnohr
Peter Schnohr
GJGorm B. Jensen
Gorm B. Jensen
The clinical significance of high heart rate in chronic obstructive pulmonary disease (COPD) is unexplored. We investigated the association between resting heart rate, pulmonary function, and prognosis in subjects with COPD.16 696 subjects aged ≥40 years from the Copenhagen City Heart Study, a prospective study of the general population, were followed for 35.3 years, 10 986 deaths occurred. Analyses were performed using time-dependent Cox-models and net reclassification index (NRI).Resting heart rate increased with severity of COPD (p<0.001). Resting heart rate was associated with both cardiovascular and all-cause mortality across all stages of COPD (p<0.001). Within each stage of COPD, resting heart rate improved prediction of median life expectancy; the difference between 85 bpm was 5.5 years without COPD, 9.8 years in mild (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage I), 6.7 years in moderate (GOLD stage II) and 5.9 years in severe/very severe COPD (GOLD stage III/IV), (p<0.001). Resting heart rate significantly improved risk prediction when added to GOLD stage (categorical NRI 4.9%, p = 0.01; category less NRI 23.0%, p<0.0001) or forced expiratory volume in 1 s % predicted (categorical NRI 7.8%, p = 0.002; category less NRI 24.1%, p<0.0001).Resting heart rate increases with severity of COPD. Resting heart rate is a readily available clinical variable that improves risk prediction in patients with COPD above and beyond that of pulmonary function alone. Resting heart rate may be a potential target for intervention in COPD.